Access the full text.
Sign up today, get DeepDyve free for 14 days.
O. Pedersen, E. Mikkelsen, N. Christensen, H. Kornerup, E. Pedersen (1979)
Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertensionEuropean Journal of Clinical Pharmacology, 15
O. Pedersen, E. Mikkelsen (1978)
Acute and chronic effects of nifedipine in arterial hypertensionEuropean Journal of Clinical Pharmacology, 14
J. Fray (1980)
Stimulus-secretion coupling of renin. Role of hemodynamic and other factors.Circulation research, 47 4
S. Bhatnagar, M. Amin, A. Al-Yusuf (1984)
Diabetogenic effects of nifedipine.British Medical Journal (Clinical research ed.), 289
L. Corea, N. Miele, M. Bentivoglio, E. Boschetti, E. Agabiti-Rosei, G. Muiesan (1979)
Acute and chronic effects of nifedipine on plasma renin activity and plasma adrenaline and noradrenaline in controls and hypertensive patients.Clinical science, 57 Suppl 5
P. Lund-johansen (1980)
Haemodynamics in essential hypertension.Clinical science, 59 Suppl 6
L. Hansson, B. Hänel (1976)
Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.British journal of clinical pharmacology, 3 4 Suppl 3
S. Charles, J. Ketelslegers, M. Buysschaert, A. Lambert (1981)
Hyperglycaemic effect of nifedipine.British Medical Journal (Clinical research ed.), 283
R. Hornung, B. Gould, R. Jones, T. Sonecha, E. Raftery (1983)
Nifedipine tablets for systemic hypertension: a study using continuous ambulatory intraarterial recording.The American journal of cardiology, 51 8
D. Giugliano, R. Torella, F. Cacciapuoti, S. Gentile, M. Verza, M. Varricchio (1980)
Impairment of insulin secretion in man by nifedipineEuropean Journal of Clinical Pharmacology, 18
E. Rowland, Thomas Evans, And, D. Krikler (1979)
Effect of nifedipine on atrioventricular conduction as compared with verapamil. Intracardiac electrophysiological study.British Heart Journal, 42
K. Aoki, T. Yoshida, S. Kato, K. Tazumi, I. Sato (1976)
Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.Japanese heart journal, 17 4
L. Heding (1975)
Radioimmunological determination of human C-peptide in serumDiabetologia, 11
G. Valdés, M. Soto, H. Croxatto, T. Bellolio, R. Corbalán, P. Casanegra (1982)
Effects of Nifedipine during Low, Normal and High Intakes of Sodium in Patients with Essential HypertensionClinical Science, 63
M. Frick, P. Pörsti (1976)
Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.British Medical Journal, 1
M. Guazzi, C. Fiorentini, M. Olivari, A. Bartorelli, G. Necchi, A. Polese (1980)
Short‐ and Long‐term Efficacy of a Calcium‐antagonistic Agent (Nifedipine) Combined with Methyldopa in the Treatment of Severe HypertensionCirculation, 61
F. Bühler, U. Hulthén, W. Kiowski, P. Bolli (1982)
Greater Antihypertensive Efficacy of the Calcium Channel Inhibitor Verapamil in Older and Low Renin PatientsClinical Science, 63
Alberto Ferrari, N. Buccino, M. Rienzo, Antonio Pedotti, G. Mancia, A. Zanchetti (1981)
Labetalol and 24‐Hour Monitoring of Arterial Blood Pressure in Hypertensive PatientsJournal of Cardiovascular Pharmacology, 3
R. Brown, A. Swander, J. McKenzie (1976)
Urine aldosterone radioimmunoassay: validation of a method without chromatography.The Journal of clinical endocrinology and metabolism, 42 5
M. Thibonnier, F. Bonnet, P. Corvol (2004)
Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertensionEuropean Journal of Clinical Pharmacology, 17
M. Burr, P. Sweetnam, R. Hurley, G. Powell (1974)
Letter: Effects of age and intake on plasma-ascorbic-acid levels.Lancet, 1 7849
M. Uusitupa, O. Siitonen, M. Härkönen, A. Gordin, A. Aro, K. Hersio, G. Johansson, T. Korhonen, R. Rauramaa (1982)
Metabolic and hormonal response to physical exercise during beta 1-selective and non-selective beta-blockade.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 14 11
G. Koch (1979)
Cardiovascular dynamics after acute and long-term alpha- and beta- adrenoceptor blockade at rest, supine and standing, and during exercise.British journal of clinical pharmacology, 8 Suppl 2
P. Weidmann, R. Châtel, W. Ziegler, J. Flammer, F. Reubi (1978)
Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion.The American journal of cardiology, 41 3
P. Bn, Boakes Aj (1976)
Labetalol in long-term treatment of hypertension.British Journal of Clinical Pharmacology, 3
A. Juhlin‐Dannfelt (2009)
Metabolic effects of beta-adrenoceptor blockade on skeletal muscle at rest and during exercise.Acta medica Scandinavica. Supplementum, 665
J. Wallin, W. O'Neill (1983)
Labetalol. Current research and therapeutic status.Archives of internal medicine, 143 3
L. Opie, D. White (1980)
Adverse interaction between nifedipine and beta-blockade.British Medical Journal, 281
H. Schenck, O. Nilsson (1981)
Radioimmunoassay of extracted glucagon compared with three non-extraction assays.Clinica chimica acta; international journal of clinical chemistry, 109 2
G. Holm (2009)
Adrenergic regulation of insulin release.Acta medica Scandinavica. Supplementum, 672
B. Hellman (1975)
The significance of calcium for glucose stimulation of insulin release.Endocrinology, 97 2
G. Gomez (1982)
The effect of different antihypertensive therapies on plasma lipids.The Practitioner, 226 1367
R. Mcgonigle, L. Williams, M. Murphy, V. Parsons (1981)
LABETALOL AND LIPIDSThe Lancet, 317
228 29 29 2 2 K. P. Öhman L. Weiner H. von Schenck B. E. Karlberg Departments of Internal Medicine Hypertension-Endocrine Unit Linköping Sweden Clinical Chemistry University Hospital Linköping Sweden Department of Internal Medicine County Hospital Karlskoga Sweden Summary In a randomised, double-blind, cross over trial, 25 patients with mild to moderate primary hypertension were given nifedipine 20–40 mg twice daily and labetalol 200–400 mg twice daily after a 4 week period on placebo, followed by the two drugs in combination. The BP during placebo therapy was 164/108 mmHg supine and 159/110 mmHg standing. After monotherapy with nifedipine for 6 weeks the supine BP was reduced by 18/13 mmHg and the standing BP by 20/12 mmHg; with labetalol the corresponding figures were 26/15 mmHg and 28/21 mmHg, respectively. The combined therapy induced a larger fall in BP, by 36/22 mmHg supine and by 39/24 mmHg standing; in 21 of 23 patients the BP became normal. The heart rate (HR) decreased during labetalol treatment alone and on the combined therapy. With nifedipine alone, the HR was unchanged in the supine position and increased on standing. Nifedipine increased plasma renin activity (PRA) and urinary aldosterone excretion (uA), whereas labetalol reduced both. During combination therapy, PRA and uA remained unchanged. There was a slight fall in HDL-cholesterol during treatment with labetalol alone and in combination with nifedipine. The fasting blood glucose increased slightly during treatment with each of the drugs, but neither caused a change in the concentrations of glycosylated haemoglobin A 1 , serum insulin, C-peptide, or plasma glucagon. Adverse effects as a rule were well tolerated and were related to the pharmacological effects of the drugs. Only 2 patients left the trial, both during labetalol treatment.
European Journal of Clinical Pharmacology – Springer Journals
Published: Mar 1, 1985
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.